News and Trends 30 Mar 2017 Merck Outsources the Development of its Nanobody for Psoriasis …Merck and the unbeaten nanobody biotech Ablynx, Merck recently cleared Phase Ib with its llama-inspired nanobody targeting the cytokines IL-17 A/F for the treatment of plaque psoriasis. The antibody is… March 30, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Jan 2023 The biggest biotech trends that will shape 2023 …its entire class.” “The fact that Roche’s own beta amyloid-directed antibody gantenerumab failed phase 3 trials adds more confusion and raises more questions than answers about the viability of this… January 12, 2023 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2018 Can MorphoSys’ Alzheimer’s Treatment Work Where Big Pharma has Failed? Roche has positive clinical data in support of starting a Phase III trial in Alzheimer’s with an antibody initially developed by MorphoSys. However, the field is full of similar approaches… March 15, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Sanofi and Innovent Biologics to collaborate on oncology medicines and boost China presence …footprint in China. Both companies said they are committed to accelerating the development and commercialization of two Sanofi key clinical stage oncology assets: Phase III SAR408701 (tusamitamab ravtansine; anti-CEACAM5 antibody-drug… August 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2022 Sanofi and Innate Pharma expand natural killer cell deal Sanofi and Innate Pharma SA have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform…. December 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Mar 2020 Labiotech.eu’s Coverage of the Covid-19 Coronavirus …Artificial Intelligence: A Superpower in the Fight Against Covid-19 The rapid spread of Covid-19 around the world has left drug developers with limited time to identify drug candidates to fight… March 19, 2020 - 13 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2022 The top European biotech investments in May 2022 …May 2022 was the German company Tubulis. The firm raised €60M in a Series B round to fund the development of antibody-drug conjugates to treat cancer. In second place, the… June 8, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II …years, there have been over 1.7 million cases across 45 countries. The virus causes sudden fever and severe joint pain, which can become chronic. Themis’ candidate is a modified measles… November 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Sep 2024 Europe’s rising biotech stars: 10 startups to watch in 2024 …Adcytherix is focused on antibody drug conjugates (ADC) against cancer. ADCs are made up of a monoclonal antibody, which is linked to a drug – usually a chemotherapy drug. ADCs… September 26, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2019 Combo of Immunotherapy and Diabetes Drug Could Beat Breast Cancer …therapy included metformin, which can inhibit tumor growth; the cancer drug venetoclax, which causes cancer cells to commit suicide; and a checkpoint inhibitor antibody, which blocks a mechanism some tumors… February 6, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Study shows enhanced drug delivery to the brain …that replicate growth factors with longer retention in the body and brain penetration. The team synthesized a molecular entity comprising two components: macrocyclic peptides inserted into antibody fragments (known as… November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 2 Nov 2017 Meet the Top Biotech Investor Who Picked His Career By Accident …PhD at Cambridge, Johnson stepped into biotech and led the development of a number of human antibodies at Cambridge Antibody Technology (CAT). The company was eventually responsible for one of… November 2, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email